710GO / Endevica - LARVOL DELTA

Kalohexis...announced its launch and spinout from Endevica Bio, a privately-held company developing first-in-class synthetic peptidomimetics. (PRNewswire) - "Kalohexis' pipeline of assets includes 710GO, a novel, oral dual MC3R/MC4R agonist designed to activate the melanocortin system to induce higher quality, durable weight loss. Kalohexis expects to initiate a first-in-human, randomized, placebo-controlled Phase 1 clinical trial of 710GO in healthy overweight and obese volunteers in the first half of 2026....A Phase 2 trial (NCT06937177) to evaluate the safety, tolerability and efficacy of mifomelatide treating cachexia in patients with advanced colorectal cancer was initiated in Q2 2025 and is currently ongoing."

Commercial • New P1 trial • Trial status • Cachexia • Colorectal Cancer • Obesity